126
Participants
Start Date
January 11, 2021
Primary Completion Date
May 18, 2022
Study Completion Date
June 30, 2022
difelikefalin 2.0 mg
Oral difelikefalin 2.0 mg administered twice daily
Placebo
Oral Placebo administered twice daily
Cara Therapeutics Study Site, New York
Cara Therapeutics Study Site, Norfolk
Cara Therapeutics Study Site, High Point
Cara Therapeutics Study Site, Charleston
Cara Therapeutics Study Site, Sandy Springs
Cara Therapeutics Study Site, Margate
Cara Therapeutics Study Site, Coral Gables
Cara Therapeutics Study Site, Miami
Cara Therapeutics Study Site, North Miami Beach
Cara Therapeutics Study Site, Columbus
Cara Therapeutics Study Site, Plainfield
Cara Therapeutics Study Site, Indianapolis
Cara Therapeutics Study Site, Metairie
Cara Therapeutics Study Site, Hot Springs
Cara Therapeutics Study Site, Rogers
Cara Therapeutics Study Site, Fort Smith
Cara Therapeutics Study Site, Bellaire
Cara Therapeutics Study Site, San Antonio
Cara Therapeutics Study Site, Pflugerville
Cara Therapeutics Study Site, Salt Lake City
Cara Therapeutics Study Site, Los Angeles
Cara Therapeutics Study Site, Santa Monica
Cara Therapeutics Study Site, San Diego
Cara Therapeutics Study Site, Fountain Valley
Cara Therapeutics Study Site, Spokane
Cara Therapeutics Study Site, Cromwell
Cara Therapeutics Study Site, Surrey
Cara Therapeutics Study Site, Winnipeg
Cara Therapeutics Study Site, Markham
Cara Therapeutics Study Site, Peterborough
Cara Therapeutics Study Site, Montreal
Cara Therapeutics Study Site, Markham
Cara Therapeutics Study Site, Montreal
Cara Therapeutics Study Site, Peterborough
Cara Therapeutics Study Site, Surrey
Cara Therapeutics Study Site, Winnipeg
Lead Sponsor
Cara Therapeutics, Inc.
INDUSTRY